Background: One of the most important dermatologic side effects of doxycycline is photosensitivity. As doxycycline is important for malaria prophylaxis and malaria is mainly spread in countries with high sun radiation, special attention should be paid to this adverse effect. While there are many publications on the phototoxicity of tetracyclines in general, only a few exist focusing on doxycycline. The objective of this systematic review was to summarize all available reports on clinical manifestations, influencing factors like UV dose or dose of medication, and the possibilities of prevention by sun protection. Methods: This review is based on a systematic search in PubMed for articles in English and German and a manual search between 1990 and 2015. Results: The number of publications is low. Clinical symptoms vary from light sunburn-like sensation (burning, erythema) to large-area photodermatitis. Also, onycholysis is possible. The triggering UV spectrum seems to consist mainly of UVA1 (340-400 nm), so UV-protective products should be used that cover this range. Travelers to tropical countries taking doxycycline for malaria prophylaxis need thorough medical counseling to avoid possibly severe phototoxic reactions. Conclusion: Evidence base must be improved for giving advice on appropriate prevention measures to travelers taking doxycycline and having a risk of significant sun exposure.

Keywords:
Phototoxicity, Photosensitivity, Doxycycline, Tetracycline
1.
WHO: Guidelines for the Treatment of Malaria, ed 3. Geneva, WHO, 2015.
2.
Layton AM, Cunliffe WJ: Phototoxic eruptions due to doxycycline - a dose-related phenomenon. Clin Exp Dermatol 1993;18:425-427.
3.
Habif TP: Images in clinical medicine. Doxycycline-induced phototoxicity. N Engl J Med 2006;355:182.
4.
Kuznetsov AV, Weisenseel P, Flaig MJ, Ruzicka T, Prinz JC: Photoallergic erythroderma due to doxycycline therapy of erythema chronicum migrans. Acta Derm Venereol 2011;91:734-736.
5.
Passier A, Smits-van Herwaarden A, van Puijenbroek E: Photo-onycholysis associated with the use of doxycycline. BMJ 2004;329:265.
6.
Pazzaglia M, Venturi M, Tosti A: Photo-onycholysis caused by an unusual beach game activity: a pediatric case of a side effect caused by doxycycline. Pediatr Dermatol 2014;31:e26-e27.
7.
Yong CK, Prendiville J, Peacock DL, Wong LT, Davidson AG: An unusual presentation of doxycycline-induced photosensitivity. Pediatrics 2000;106:E13.
8.
Rabar D, Combemale P, Peyron F: Doxycycline-induced photo-onycholysis. J Travel Med 2004;11:386-387.
9.
Susong J, Carrizales S: Lichenoid photosensitivity: an unusual reaction to doxycycline and an unusual response. Cutis 2014;93:E1-E2.
10.
Lim DS, Triscott J: O'Brien's actinic granuloma in association with prolonged doxycycline phototoxicity. Australas J Dermatol 2003;44:67-70.
11.
Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, Upchurch GR Jr, Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW: Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 2002;36:1-12.
12.
Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, Wisniewski M, Collins JJ: Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995;39:661-667.
13.
Lim DS, Murphy GM: High-level ultraviolet a photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor. Br J Dermatol 2003;149:213-214.
14.
Bjellerup M, Ljunggren B: Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 1994;130:356-360.
15.
Nowakowski J, Nadelman RB, Forseter G, McKenna D, Wormser GP: Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol 1995;32:223-227.
16.
Pathak M: Photoprotection against harmful effects of solar UVB and UVA radiation: an update; in Sunscreens: Development, Evaluation, and Regulatory Aspects. New York, Marcel Dekker, 1997, pp 59-82.
17.
Baron ED, Stevens SR: Sunscreens and immune protection. Br J Dermatol 2002;146:933-937.
18.
Elsner P, Hölzle E, Diepgen T, Grether-Beck S, et al: Recommendation: daily sun protection in the prevention of chronic UV-induced skin damage. J Dtsch Dermatol Ges 2007;5:166-173.
19.
Tanaka N, Kawada A, Ohnishi Y, Hiruma M, Tajima S, Akiyama M, Ishibashi A: Photosensitivity due to doxycycline hydrochloride with an unusual flare. Contact Dermatitis 1997;37:93-94.
20.
Ogrinc K, Logar M, Lotric-Furlan S, Cerar D, Ruzic-Sabljic E, Strle F: Doxycycline versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis. Wien Klin Wochenschr 2006;118:696-701.
21.
Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Cimperman J: Azithromycin and doxycycline for treatment of borrelia culture-positive erythema migrans. Infection 1996;24:64-68.
22.
Hafiji J, Batchelor J: Red in the face. BMJ 2010;340:b5643.
23.
Kus S, Yucelten D, Aytug A: Comparison of efficacy of azithromycin versus doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005;30:215-220.
24.
Schuhwerk M, Behrens RH: Doxycycline as first line malarial prophylaxis: how safe is it? J Travel Med 1998;5:102.
25.
Thalmann H, Muller JB: Suspected borreliosis: therapy is incompatible with the French sun (in German). MMW Fortschr Med 2009;151:5.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.